Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: Abstracts from the 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)

Open Access Open Badges Poster presentation

Human beta-defensins induce APOBEC3G expression by interacting with chemokine receptors, protecting highly susceptible cells from HIV infection

Alfredo Garzino-Demo*, Mark K Lafferty, Jennifer Bharucha, Lingling Sun, Walter Royal, Suzanne Gartner and Wuyuan Lu

Author Affiliations

Institute of Human Virology, U. Maryland School of Medicine, Baltimore, USA

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 1):P8  doi:10.1186/1742-4690-9-S1-P8

The electronic version of this article is the complete one and can be found online at:

Published:25 May 2012

© 2012 Garzino-Demo et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Poster presentation

ß-defensins are antimicrobial peptides secreted by epithelial cells that can bind to cellular receptors. CCR2 and CCR6 are the two cellular receptors known to bind human ß-defensin (hBD) 2 and -3. Both of these receptors are of crucial relevance in HIV infection. CCR6 is expressed, often in concert with CCR5, on cells that are highly susceptible to HIV infection: memory T cells, Th17 cells, α4ß7+ cells, and defects in CD4+CCR6+ cells have been associated with faster AIDS progression. CCR2 is expressed on monocytes and macrophages, cells that are reservoirs of HIV infection and that are known to mediate central nervous system damage. Our studies show that hBD2, hBD3, and CCR6 ligand MIP-3α/CCL20 inhibit HIV infection via CCR6 by increasing expression of the antiviral protein APOBEC3G. This increase is due to a transcriptional mechanism mediated by intracellular signaling. hBD2 also inhibits HIV replication in macrophages that express CCR2. Our findings suggest novel therapeutic and preventive approaches that exploit CCR6 and CCR2-mediated intracellular signaling to inhibit HIV infection in highly susceptible cells.